US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.82 against a street estimate of 1.67 — a beat of 9.0%.
Analysts rate ANI Pharmaceuticals Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $108.38.
MIXED ANI reported strong Q2 growth driven by Cortrophin (up 43% YoY to $117.1M), modest Cortrophin guidance cut for FY26, and early positive traction from new gout sales force expansion launched late Q2. Q2 2026 Call did not discuss geographic segments. Analysts pressed management on guidance revision disconnect (guidance cut despite Q2 beat), payer mix differences in gout vs. base, and M&A appetite. Management deflected on specifics (gout flares, prescriber penetration, G2N pressure) citing competitive sensitivity but reiterated strong leading indicators and H2 confidence without quantifying patient-level dynamics. 2026-08-07…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.96% |
| Soleus Capital Management, L.P. | 3.78% |
| Vanguard Capital Management, LLC | 3.58% |
| State Street Corp | 3.36% |
| TANG CAPITAL MANAGEMENT LLC | 3.08% |
| Dimensional Fund Advisors, Inc. | 2.71% |
| American Century Companies Inc | 2.50% |
| Arrowstreet Capital Limited Partnership | 2.46% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 ANI PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Filing Date: August 24, 2026 (reporting events from August 19 and August 23, 2026) • | 2026-08-24 |
| Quarterly report · Q2 2026 ANI PHARMACEUTICALS, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Revenues (6M 2026): $503.5 million vs. $408.5 million (6M 2025) — increase o | 2026-08-07 |
| Results announced · Q3 2026 ANI PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Total Net Revenues: $266.0 million – up 25.9% year-over-year • Q2 2026 GAAP | 2026-08-07 |
| Board / officer change · Q2 2026 ANI PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 21, 2026 • 22,750,198 shares of Common Stock outstanding as | 2026-05-21 |
| Reg FD disclosure · Q2 2026 ANI PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics or headline numbers are disclosed in this Form 8-K fil | 2026-05-13 |
| Quarterly report · Q1 2026 ANI PHARMACEUTICALS, INC. - Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net Revenues: $237.5 million for Q1 2026, up from $197.1 million in Q1 2025 | 2026-05-08 |
| Proxy statement · Q4 2025 ANI PHARMACEUTICALS, INC. — PROXY STATEMENT SUMMARY CEO COMPENSATION • Nikhil Lalwani (CEO) total 2025 compensation: Not specified in provided docum | 2026-04-09 |
| Annual report FY2025 ANI PHARMACEUTICALS, INC. - 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Market capitalization as of June 30, 2025: $1.3 billion (stock price $65.25 pe | 2026-02-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| Preliminary 2025 results and 2026 financial guidance provided ANI Pharmaceuticals announced preliminary unaudited financial results for Q4 and full year 2025, along with 2026 guidance on January 12, 2026. The company's CEO will present at the J.P. Morg | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ANI Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.